海翔药业（002099）披露2025年度业绩预告，1月28日股价上涨1.28%

Group 1 - The core point of the article is that Zhejiang Haixiang Pharmaceutical Co., Ltd. has released its 2025 annual performance forecast, indicating a projected net loss for shareholders of the listed company between -135 million yuan and -90 million yuan, with a narrowed loss compared to the previous year [1] - The forecasted net profit after deducting non-recurring gains and losses is expected to be between -142 million yuan and -95 million yuan, with basic earnings per share projected to be between -0.08 yuan and -0.06 yuan [1] - The main reasons for the performance changes include pressure on gross margins due to fluctuations in product prices and rising raw material costs in the pharmaceutical sector, while the dye sector has seen a recovery in profitability due to price increases of core products [1] Group 2 - The exchange rate of the US dollar against the Chinese yuan has had a significant negative impact on net profit [1] - The performance forecast has not been audited and there are no significant disagreements with the accounting firm [1]